Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)
NCT ID: NCT06892210
Last Updated: 2025-03-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE4
2000 participants
INTERVENTIONAL
2025-08-01
2026-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will randomized to receive treatment with either hydrocortisone or prednisolone.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Corticosteroid Reduction in COPD
NCT02857842
Steroid Resistance During COPD Exacerbations With Respiratory Failure
NCT03680495
Efficacy of Corticosteroids to Treat Outpatients With Acute Exacerbations of COPD
NCT02330952
The Doses of Systemic Steroid in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)
NCT01215825
Eosinophil-driven Corticotherapy for Patients Hospitalized for COPD Exacerbation
NCT04234360
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment with Hydrocortisone.
This arm will recieve a dose of 200 mg of Hydrocortisone intravenously once daily for five days.
Hydrocortisone
ATC-code: H02AB09. Can be changed to 50 mg x 4 daily orally if appropriate.
Treatment with Methylprednisolone
This arm will recieve a dose of 40 mg of Methylprednisolone intravenously once daily for five days.
Methylprednisolone (drug)
ATC code: H02AB06. Can be changed to Prednisolone 50 mg orally.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Methylprednisolone (drug)
ATC code: H02AB06. Can be changed to Prednisolone 50 mg orally.
Hydrocortisone
ATC-code: H02AB09. Can be changed to 50 mg x 4 daily orally if appropriate.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chronic obstructive pulmonary disease with acute exacerbation, unspecified: ICDJ44
Exclusion Criteria
* Pregnant or breastfeeding women
* Active tuberculosis or invasive fungal infection
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Copenhagen Respiratory Research
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jens-Ulrik Stæhr Jensen, MD, PHD
Role: STUDY_DIRECTOR
COP:RESP
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MineraloCOP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.